Skip to contentE
Endonovo Therapeutics, Inc.
E
ENDVEndonovo Therapeutics, Inc. Q3 2023 · 10-Q
Revenue$1.52K$1.52K−86.1% vs Q3 2022 Net Income-$766.17K-$766.17KN/M vs Q3 2022 EPS Diluted$0.00$0.00— vs Q3 2022 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR
Operating Cash Flowderived-$65,367N/M Margins · derivedGross margin45.6%−17.7 pt vs Q3 2022
Operating margin-31105.1%−26572.4 pt vs Q3 2022
Net margin-50405.9%−44900.8 pt vs Q3 2022
ended Sep 30, 2023 · filed Dec 29, 2023 · 90 d after period end